Status:

TERMINATED

People Presenting With Neurocysticercosis in North America

Lead Sponsor:

National Institute of Allergy and Infectious Diseases (NIAID)

Conditions:

Neurocysticercosis

Eligibility:

All Genders

18+ years

Brief Summary

Background: \- Neurocysticercosis (NCC) is caused by tapeworms that infect people. NCC can lead to serious brain problems such as seizures, sevre headaches and difficulties with movements or sensatio...

Detailed Description

Neurocysticercosis (NCC) is the most common helminthic CNS infection and the main cause of adult-onset seizures in low-to-middle income countries. Studies have documented significant endemicity in Lat...

Eligibility Criteria

Inclusion

  • INCLUSION CRITERIA:
  • Adults greater than or equal to18 years of age.
  • Subject, or Subject s Legally Authorized Representative (LAR)/ Durable Power of Attorney (DPA), is able to provide informed consent and agree to allow samples to be stored for future research.
  • Previously or currently diagnosed with definitive or probable NCC by a practitioner at NACC in accordance with the Del Brutto criteria modified for use in a North American populations.
  • For the purpose of this study, definitive and probable diagnostic certainty based on presence of criteria below.
  • Definitive diagnosis
  • Presence of 1 absolute criterion
  • Presence of 2 major + 1 minor + 1 epidemiological criterion
  • Probable diagnosis Presence of 1 major + 2 minor criterion
  • Presence of 1 major + 1 minor + 1 epidemiological criterion
  • Presence of characteristic calcification(s)
  • Del Brutto Diagnostic criteria
  • Absolute criteria
  • Biopsy of a brain or spinal cord lesion
  • Cystic lesion with scolex on CT or MRI
  • Fundoscopic examination (subretinal parasites)
  • Major criteria
  • Highly suggestive lesions on neuroimaging
  • Positive serum enzyme-linked immunotransfer blot (EITB) assay
  • Resolution of intracranial cysts after therapy
  • Spontaneous resolution of small single enhancing lesions
  • Minor criteria
  • Compatible lesions on neuroimaging
  • Clinical manifestations suggestive for NCC (eg, headaches, seizures, neurological symptoms)
  • Positive CSF ELISA for specific Ag/Ab
  • Cysts outside CNS
  • Epidemiological criteria
  • Evidence of household contact with T. solium
  • Individuals coming from/living in endemic areas
  • History of frequent travel to endemic areas
  • Single or multiple characteristic calcifications in subjects who meet epidemiologic criteria (4) without another identifiable etiology will be considered NCC in the case of calcified granulomas
  • EXCLUSION CRITERIA:
  • 1\. Subjects that in the opinion of the investigator have contraindications for participation in the study will be excluded, such as patients with current substance abuse or patients currently undergoing cancer chemotherapy.
  • Justification for Exclusion or Inclusion of Special Populations
  • Children
  • Children are eligible to participate in this clinical trial but will not be enrolled at the NIH because the NIH investigators do not see nor specialize in pediatric populations. In addition, NCC in the U.S. generally afflicts travelers and immigrants and is therefore exceedingly rare in pediatric populations in the U.S.
  • Adults Unable To Provide Consent-
  • Patients will be offered standard of care treatment delivered irrespective of cognitive status, including lumbar punctures that are used clinical management decisions as determined by the site PI. Exclusion of patients unable to provide consent because of cognitive impairment would limit the study population significantly, and potentially compromise the generalizability of results from this observational study. In cases where cognitive function precludes informed consent we will seek consent from the designated legal guardian.

Exclusion

    Key Trial Info

    Start Date :

    September 3 2014

    Trial Type :

    OBSERVATIONAL

    Allocation :

    ACTUAL

    End Date :

    June 13 2017

    Estimated Enrollment :

    11 Patients enrolled

    Trial Details

    Trial ID

    NCT02233855

    Start Date

    September 3 2014

    End Date

    June 13 2017

    Last Update

    April 5 2018

    Active Locations (4)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (4 locations)

    1

    University of California San Francisco

    San Francisco, California, United States, 94110

    2

    National Institutes of Health Clinical Center, 9000 Rockville Pike

    Bethesda, Maryland, United States, 20892

    3

    UT Southwestern Medical Center

    Dallas, Texas, United States, 75390

    4

    University of Washington

    Seattle, Washington, United States, 98195